Industries > Pharma > Mental Disorder Drugs Market Report 2021-2031
Mental Disorder Drugs Market Report 2021-2031
Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios
Mental Disorder Drugs Market – reveals latest trends, opportunities, predicted revenues, and competitive analysis. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.
Global mental disorder drugs market is projected to reach at a market value of US$xx billion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of mental disorders including depression, bipolar disorder, anxiety, and schizophrenia is a major factor that drives the demand for mental disorder drugs. Other key drivers boosting the market growth are growing mental health awareness in developing countries; adoption of mental disorder drugs for treatment & maintenance therapy; and rising R&D investment by the leading pharmaceutical companies in the area of mental health. In addition, the COVID-19 pandemic has a significant impact on the mental disorder drugs market. The COVID-19 pandemic has resulted in a growing incidence of mental disorders due to unemployment, financial crisis, health issues, and stress. Thus, the demand for mental disorder drugs is expected to rise during the forecast period.
Visiongain’s report shows you the potential revenues streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the mental disorder drugs industry.
To access the data contained in this document please email contactus@visiongain.com
How this report will benefit you
Visiongain’s new study is envisioned for anyone requiring commercial in-depth analyses for the global mental disorder drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for mental disorder drugs. Get the financial analysis of the overall market and different segments including by drug class, route of administration, usability, and distribution channel. High opportunity remains in this fast-growing mental disorder drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefit in the near future. Moreover, the report would help you to improve your strategic decision making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise productivity of the company.
Forecasts to 2031 and other analyses reveal the commercial prospects
• Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
• It also includes growth rates for different 5 regional markets along with 18 countries and COVID-19 impact analysis on each market
• The profiles of the top 15 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
• The COVID-19 has a positive impact on the mental disorder drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Discover sales forecasts for the global and regional market forecasts from 2021-2031
Along with revenue prediction for the overall global market, there is segmentation by region for 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA and 20 major countries.
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class
• SSRIs
• SNRIs
• Atypical Antipsychotics
• TCAs
• SARIs
• Benzodiazepines
• MAOIs
• Others
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication
• Depression
• Schizophrenia
• Bipolar disorder
• Post-traumatic Stress Disorder
• Others
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Others
Regional market revenue and growth forecasts from 2021 to 2031:
• North America
– U.S.
– Canada
• Europe
– Germany
– UK
– France
– Italy
– Spain
– Russia
– Rest of Europe
• Asia Pacific
– Japan
– China
– India
– Australia
– South Korea
– Rest of Asia Pacific
• Latin America
– Brazil
– Mexico
– Argentina
– Rest of Latin America
• Middle East and Africa
– South Africa
– Saudi Arabia
– Rest of MEA
Need industry data? Please contact us today.
Detailed profiles of 15 leading companies that are operating in the market
The report includes profiles of 15 major companies involved in the mental disorder drugs market. The companies profiled in this report include: AbbVie, AstraZeneca, Bausch Health, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Teva Pharmaceutical Industries.
Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
In summary, our 429-page report delivers you with the following knowledge:
• Revenue forecasts from 2021 to 2031 for the global mental disorder drugs market and subsegments (by drug class, indication, distribution channel, and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
• Detailed profiles of top 15 mental disorder drugs manufacturers, with financial overviews for net revenues, operating income, R&D investment, and segment revenues
• Revenue forecasts from 2021 to 2031 for 5 regional markets – See forecasts for the mental disorder drugs market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the mental disorder drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.
The Mental Disorder Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the mental disorder drugs industry.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Mental Disorder Drugs Market Report 2021-2031: Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Introduction to Mental Disorder Drugs Market
1.1.1 What Is Mental Disorder?
1.1.2 Types of Mental Disorders
1.1.3 Prevalence and Mortality for Mental Disorders
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered By This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecast Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Development of Advanced Mental Disorder Drugs
3.1.2 Increasing Prevalence of Mental Disorders
3.1.3 Escalating of Mental Healthcare Awareness
3.2 Restraints
3.2.1 Increasing Development of Novel Drugs
3.2.2 Social Stigma of Mental Disorders
3.2.3 Stringent Regulatory Guidelines for New Drug Approval
3.3 Opportunities
3.3.1 Growing Demand for Cutting-Edge Therapeutic Treatments for Mental Disorders to Aid Market Growth
3.3.2 Increase in Geriatric Population
3.4 Trends
3.4.1 Mergers, Agreements, and Acquisitions by the Market Players
3.4.2 Expected Launch of New Drugs is Expected to Drive the Market Growth
3.5 SWOT Analysis
3.5.1 Strengths: The Most Dynamic Area of the Mental Disorders Market
3.5.2 Weaknesses
3.5.3 Opportunities
3.5.3.1 Increasing Mergers & Acquisitions and Collaborations
3.5.3.2 Large Amount of R&D Investment
3.5.4 Threats
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Supplier: Moderate
3.6.2 Bargaining Power of Buyer: Moderate
3.6.3 Competitive Rivalry: High
3.6.4 Threat of New Entrants: Moderate
3.6.5 Threat of Substitutes: Moderate
3.7 PEST Analysis
3.7.1 Political Factors Impacting Mental Disorder Drugs Market
3.7.2 Economic Factors Impacting Mental Disorder Drugs Market
3.7.3 Social Factors Impacting Mental Disorder Drugs Market
3.7.4 Technological Factors Impacting Mental Disorder Drugs Market
4 Global Mental Disorder Drugs Market Forecast, 2021-2031
4.1 Global Mental Disorder Drugs Market Forecast 2021-2031
5 COVID-19 Impact: Global Mental Disorder Drugs Market
5.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
5.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
5.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
5.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Drug Class
6.1 Global SSRIs Segment: Revenue Forecast 2021-2031
6.1.1 Largest Revenue Grossing Segment
6.1.2 Recovery Forecasts (V, U, W, L)
6.2 Global SNRIs Segment: Revenue Forecast 2021-2031
6.2.1 Increase in Adoption of These Drugs for the Treatment of Mental Disorders
6.2.2 Recovery Forecasts (V, U, W, L)
6.3 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031
6.3.1 Atypical Antipsychotics Segment is Expected to Grow at a Lucrative Growth Rate
6.3.2 Recovery Forecasts (V, U, W, L)
6.4 Global TCAs Segment: Revenue Forecast 2021-2031
6.4.1 TCAs Play an In the Treatment of Severe Depression
6.4.2 Recovery Forecasts (V, U, W, L)
6.5 Global SARIs Segment: Revenue Forecast 2021-2031
6.5.1 SARIs Are Mainly Used For The Treatment MDD
6.5.2 Recovery Forecasts (V, U, W, L)
6.6 Global Benzodiazepines Segment: Revenue Forecast 2021-2031
6.6.1 Benzodiazepines Segment is Presumed to Witness Moderate Growth over the Forecast Period
6.6.2 Recovery Forecasts (V, U, W, L)
6.7 Global MAOIs Segment: Revenue Forecast 2021-2031
6.7.1 MAOIs Segment Expected To Witness Lucrative CAGR during the Forecast Period
6.7.2 Recovery Forecasts (V, U, W, L)
6.8 Global Others Segment: Revenue Forecast 2021-2031
6.8.1 Growing Demand for Advanced Drugs Is Expected to Propel the Segment Growth
6.8.2 Recovery Forecasts (V, U, W, L)
7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Indication
7.1 Global Depression Segment: Revenue Forecast 2021-2031
7.1.1 Largest Revenue Grossing Segment
7.1.2 Recovery Forecasts (V, U, W, L)
7.2 Global Schizophrenia Segment: Revenue Forecast 2021-2031
7.2.1 Mounting Prevalence of Schizophrenia Worldwide Will Drive the Segment Growth
7.2.2 Recovery Forecasts (V, U, W, L)
7.3 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031
7.3.1 Adoption of Generic Drugs for the Treatment of Bipolar Disorder
7.3.2 Recovery Forecasts (V, U, W, L)
7.4 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031
7.4.1 Growing R&D expenditure in the development of therapeutically advanced mental disorder drugs
7.4.2 Recovery Forecasts (V, U, W, L)
7.5 Global Others Segment: Revenue Forecast 2021-2031
7.5.1 Rising Prevalence of Other Mental Disorders
7.5.2 Recovery Forecasts (V, U, W, L)
8 Mental Disorder Drugs Market by Distribution Channel Forecast, 2021-2031
8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
8.1.1 Largest Revenue Generating Segment
8.1.2 Recovery Scenarios (V, U, W, L)
8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
8.2.1 Fastest Growing Segment in the Market
8.2.2 Recovery Scenarios (V, U, W, L)
8.3 Others Segment Market Forecast, 2021-2031
8.3.1 Developing Healthcare Infrastructure Is Expected To Drive the Market Growth
8.3.2 Recovery Scenarios (V, U, W, L)
9 Global Mental Disorder Drugs Market Forecast, 2021-2031
9.1 Global Mental Disorder Drugs Market by Region Forecast 2021-2031
9.2 Recovery Scenarios (V, U, W, L)
10 North America Mental Disorder Drugs Market, 2021-2031
10.1 North America is The Largest Revenue Grossing Region in the Global Market
10.2 North America Mental Disorder Drugs Market by Country, Forecast 2021-2031
10.3 Recovery Scenarios (V, U, W, L)
10.4 North America Mental Disorder Drugs Market Forecast by Drug Class
10.5 North America Mental Disorder Drugs Market Forecast by Indication
10.6 North America Mental Disorder Drugs Market Forecast by Distribution Channel
10.7 U.S. Mental Disorder Drugs Market Forecast, 2021-2031
10.7.1 Rise in the Number of Drug Approvals
10.7.2 Presence of Highly Developed Healthcare Infrastructure
10.7.3 Recovery Scenarios (V, U, W, L): U.S. Mental Disorder Drugs Market Forecast, 2021-2031
10.8 Canada Mental Disorder Drugs Market Forecast, 2021-2031
10.8.1 Anticipated To Witness the Fastest Growth in the North America Region
10.8.2 Benefits of Manufacturing and R&D Operations in Canada
10.8.3 Recovery Scenarios (V, U, W, L): Canada Mental Disorder Drugs Market Forecast, 2021-2031
11 Europe Mental Disorder Drugs Market, 2021-2031
11.1 Second Largest Market in the Global Market
11.2 Europe Mental Disorder Drugs Market by Country, Forecast 2021-2031
11.3 Recovery Scenarios (V, U, W, L)
11.4 Europe Mental Disorder Drugs Market Forecast by Drug Class
11.5 Europe Mental Disorder Drugs Market Forecast by Indication
11.6 Europe Mental Disorder Drugs Market Forecast by Distribution Channel
11.7 Germany Mental Disorder Drugs Market Forecast, 2021-2031
11.7.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
11.7.2 One of the Oldest Universal Health Systems within Europe
11.7.3 Recovery Scenarios (V, U, W, L): Germany Mental Disorder Drugs Market Forecast, 2021-2031
11.8 UK Mental Disorder Drugs Market Forecast, 2021-2031
11.8.1 Presence of Well-Developed R&D Infrastructure
11.8.2 Increasing Prevalence of Mental Disorders in This Region
11.8.3 Recovery Scenarios (V, U, W, L): UK Mental Disorder Drugs Market Forecast, 2021-2031
11.9 France Mental Disorder Drugs Market Forecast, 2021-2031
11.9.1 Growing Demand For Affordable Healthcare Services
11.9.2 Growing Demand for Innovative Medicine and Pharmaceutical
11.9.3 Recovery Scenarios (V, U, W, L): France Mental Disorder Drugs Market Forecast, 2021-2031
11.10 Italy Mental Disorder Drugs Market Forecast, 2021-2031
11.10.1 Pharmaceutical Manufacturing Hub
11.10.2 Growing Demand for Advanced Therapies for the Treatment of Mental Disorders
11.10.3 Recovery Scenarios (V, U, W, L): Italy Mental Disorder Drugs Market Forecast, 2021-2031
11.11 Spain Mental Disorder Drugs Market Forecast, 2021-2031
11.11.1 Spanish Economy Is Growing Strong
11.11.2 Demand for Drugs Is Influenced By the Growth of the Pharmaceutical Industry
11.11.3 Recovery Scenarios (V, U, W, L): Spain Mental Disorder Drugs Market Forecast, 2021-2031
11.12 Russia Mental Disorder Drugs Market Forecast, 2021-2031
11.12.1 Unmet Pharmaceutical Needs
11.12.2 Government Support For Development of the Healthcare Infrastructure
11.12.3 Recovery Scenarios (V, U, W, L): Russia Mental Disorder Drugs Market Forecast, 2021-2031
11.13 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
11.13.1 Increasing Prevalence of Mental Disorders
11.13.2 Recovery Scenarios (V, U, W, L): Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
12 Asia Pacific Mental Disorder Drugs Market, 2021-2031
12.1 Asia Pacific is the Fastest Growing Market
12.2 Asia Pacific Mental Disorder Drugs Market by Country, Forecast 2021-2031
12.3 Recovery Scenarios (V, U, W, L)
12.4 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class
12.5 Asia Pacific Mental Disorder Drugs Market Forecast by Indication
12.6 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel
12.7 Japan Mental Disorder Drugs Market Forecast, 2021-2031
12.7.1 Japan Accounted For the Largest Market Share in the Asia Pacific Region
12.7.2 Government Initiatives
12.7.3 Recovery Scenarios (V, U, W, L): Japan Mental Disorder Drugs Market Forecast, 2021-2031
12.8 China Mental Disorder Drugs Market Forecast, 2021-2031
12.8.1 Presence of Large Geriatric Population
12.8.2 Increasing Healthcare Spending In China
12.8.3 Recovery Scenarios (V, U, W, L): China Mental Disorder Drugs Market Forecast, 2021-2031
12.9 India Mental Disorder Drugs Market Forecast, 2021-2031
12.9.1 Developing Healthcare Infrastructure
12.9.2 Increasing Prevalence of Mental Disorders
12.9.3 Recovery Scenarios (V, U, W, L): India Mental Disorder Drugs Market Forecast, 2021-2031
12.10 Australia Mental Disorder Drugs Market Forecast, 2021-2031
12.10.1 Government Programs to Expand Access to Quality Eye Care Facilities
12.10.2 Well Established Healthcare Infrastructure
12.10.3 Recovery Scenarios (V, U, W, L): Australia Mental Disorder Drugs Market Forecast, 2021-2031
12.11 South Korea Mental Disorder Drugs Market Forecast, 2021-2031
12.11.1 Growing Healthcare Awareness among People
12.11.2 Increasing Prevalence of Depression
12.11.3 Recovery Scenarios (V, U, W, L): South Korea Mental Disorder Drugs Market Forecast, 2021-2031
12.12 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
12.12.1 Rising Disposable Income
12.12.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
13 Latin America Mental Disorder Drugs Market, 2021-2031
13.1 Latin America Mental Disorder Drugs Market
13.2 Latin America Mental Disorder Drugs Market by Country, Forecast 2021-2031
13.3 Recovery Scenarios (V, U, W, L)
13.4 Latin America Mental Disorder Drugs Market Forecast by Drug Class
13.5 Latin America Mental Disorder Drugs Market Forecast by Indication
13.6 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel
13.7 Brazil Mental Disorder Drugs Market Forecast, 2021-2031
13.7.1 Fastest Growing Economies in Latin America
13.7.2 Government Incentives to Keep Manufacturing Local
13.7.3 Recovery Scenarios (V, U, W, L): Brazil Mental Disorder Drugs Market Forecast, 2021-2031
13.8 Mexico Mental Disorder Drugs Market Forecast, 2021-2031
13.8.1 Lower Manufacturing Costs than In the US
13.8.2 Favourable Initiatives Undertaken By Private and Public Sectors
13.8.3 Recovery Scenarios (V, U, W, L): Mexico Mental Disorder Drugs Market Forecast, 2021-2031
13.9 Argentina Mental Disorder Drugs Market Forecast, 2021-2031
13.9.1 Boom in Pharmaceutical Industry
13.9.2 Adoption of Depression and Other Mental Disorders Drugs
13.9.3 Recovery Scenarios (V, U, W, L): Argentina Mental Disorder Drugs Market Forecast, 2021-2031
13.10 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
13.10.1 Developing Healthcare Infrastructure
13.10.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
14 MEA Mental Disorder Drugs Market, 2021-2031
14.1 Rising Prevalence of Mental Disorders
14.2 MEA Mental Disorder Drugs Market by Country, Forecast 2021-2031
14.3 Recovery Scenarios (V, U, W, L)
14.4 MEA Mental Disorder Drugs Market Forecast by Drug Class
14.5 MEA Mental Disorder Drugs Market Forecast by Indication
14.6 MEA Mental Disorder Drugs Market Forecast by Distribution Channel
14.7 South Africa Mental Disorder Drugs Market Forecast, 2021-2031
14.7.1 Increasing Focus of Pharmaceutical & Pharmaceutical Companies in This Region
14.7.2 Supportive Government Initiatives
14.7.3 Recovery Scenarios (V, U, W, L): South Africa Mental Disorder Drugs Market Forecast, 2021-2031
14.8 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
14.8.1 Presence of Huge Growth Opportunities
14.8.2 Presence of Huge Growth Opportunities
14.8.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
14.9 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
14.9.1 Strong Presence Of Leading Companies
14.9.2 Growing Prevalence of Mental Disorders
14.9.3 Recovery Scenarios (V, U, W, L): Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
15 Company Profiles
15.1 Company Share Analysis
15.2 Mental Disorder Drugs Market Recent Developments, 2017-2020
15.3 Novartis AG
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2015-2019
15.3.3.2 Product Revenue Shares, 2019
15.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
15.3.3.4 Regional Revenue Shares, 2019
15.3.4 Product Benchmarking
15.3.5 Recent Developments, 2017-2020
15.4 GlaxoSmithKline Pharmaceuticals Ltd.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2015-2019
15.4.3.2 Product Revenue Shares, 2019
15.4.3.3 Pharmaceuticals Segment Revenue Shares, 2019
15.4.3.4 Regional Revenue Shares, 2019
15.4.4 Product Benchmarking
15.4.5 Recent Developments, 2017-2020
15.5 Pfizer Inc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2015-2019
15.5.3.2 Product Revenue Shares, 2019
15.5.3.3 Regional Revenue Shares, 2019
15.5.4 Product Benchmarking
15.5.5 Recent Developments, 2017-2020
15.6 AbbVie Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2015-2019
15.6.3.2 Product Revenue Shares, 2019
15.6.3.3 Regional Revenue Shares, 2019
15.6.4 Product Benchmarking
15.6.5 Recent Developments, 2017-2020
15.7 Johnson & Johnson
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2015-2019
15.7.3.2 Product Revenue Shares, 2019
15.7.3.3 Regional Revenue Shares, 2019
15.7.4 Product Benchmarking
15.7.5 Recent Developments, 2017-2020
15.8 AstraZeneca
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2015-2019
15.8.3.2 Product Revenue Shares, 2019
15.8.3.3 Regional Revenue Shares, 2019
15.8.4 Product Benchmarking
15.8.5 Recent Developments, 2017-2020
15.9 Otsuka Pharmaceuticals
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Recent Developments, 2017-2020
15.10 Eli Lilly and Company
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2015-2019
15.10.3.2 Product Revenue Shares, 2019
15.10.3.3 Regional Revenue Shares, 2019
15.10.4 Product Benchmarking
15.10.5 Recent Developments, 2017-2020
15.11 H. Lundbeck A/S
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2015-2019
15.11.3.2 Regional Revenue Shares, 2019
15.11.4 Product Benchmarking
15.11.5 Recent Developments, 2017-2020
15.12 Takeda Pharmaceutical Company Ltd.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2015-2019
15.12.3.2 Regional Revenue Shares, 2019
15.12.4 Product Benchmarking
15.12.5 Recent Developments, 2017-2020
15.13 Bausch Health
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2015-2019
15.13.3.2 Product Revenue Shares, 2019
15.13.3.3 Regional Revenue Shares, 2019
15.13.4 Product Benchmarking
15.14 Mallinckrodt Pharmaceuticals
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2015-2019
15.14.3.2 Product Revenue Shares, 2019
15.14.3.3 Regional Revenue Shares, 2019
15.14.4 Product Benchmarking
15.15 Teva Pharmaceutical Industries Ltd.
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2015-2019
15.15.3.2 Product Revenue Shares, 2019
15.15.3.3 Regional Revenue Shares, 2019
15.15.4 Product Benchmarking
15.15.5 Recent Developments, 2017-2020
15.16 Merck & Co., Inc.
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Financial Analysis
15.16.3.1 Net Revenue, 2015-2019
15.16.3.2 Product Revenue Shares, 2019
15.16.3.3 Regional Revenue Shares, 2019
15.16.4 Product Benchmarking
15.17 Bristol-Myers Squibb
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Financial Analysis
15.17.3.1 Net Revenue, 2015-2019
15.17.3.2 Regional Revenue Shares, 2019
15.17.4 Product Benchmarking
15.17.5 Recent Developments, 2017-2020
16 Conclusion and Recommendations
16.1 Conclusion
16.2 Recommendations
List of Tables
Table 1 Mental Disorder Types
Table 2 Global Mental Disorder Drugs Market, 2021 & 2031 (US$ bn, CAGR %)
Table 3 Worldwide Mental Disorders Prevalence, 2017
Table 4 Major M&A and Collaborations: Mental Disorder Drugs Market
Table 5 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
Table 6 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
Table 7 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
Table 8 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
Table 9 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
Table 10 Global Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 11 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 12 “V” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 13 “U” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 14 “W” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 15 “L” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 16 Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 17 “V” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 18 “U” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 19 “W” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 20 “L” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 21 Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 22 “V” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 23 “U” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 24 “W” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 25 “L” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 26 Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 27 “V” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 28 “U” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 29 “W” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 30 “L” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 31 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 32 “V” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 33 “U” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 34 “W” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 35 “L” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 36 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 37 “V” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 38 “U” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 39 “W” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 40 “L” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 41 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 42 “V” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 43 “U” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 44 “W” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 45 “L” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 46 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 47 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 48 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 49 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 50 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 51 Global Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 53 “V” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 54 “U” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 55 “W” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 56 “L” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 58 “V” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 59 “U” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 60 “W” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 61 “L” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 63 “V” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 64 “U” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 65 “W” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 66 “L” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 68 “V” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 69 “U” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 70 “W” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 71 “L” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 73 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 74 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 75 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 76 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 77 Global Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 88 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 89 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 90 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 91 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 92 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 93 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 94 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 95 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 96 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 97 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 98 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 99 North America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 100 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 101 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 102 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 103 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 104 North America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 105 North America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 117 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 118 Europe Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 119 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 120 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 121 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 122 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 123 Europe Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 124 Europe Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR %)
Table 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 161 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 163 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 164 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 165 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 166 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 167 Asia Pacific Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 168 Asia Pacific Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 200 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 201 Latin America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 202 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 203 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 1 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 204 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 205 Latin America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 206 Latin America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 207 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 208 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 213 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 218 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 223 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 2 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 228 MEA Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 229 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 230 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 231 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 232 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 233 MEA Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 234 MEA Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 235 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 236 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 237 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 241 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 242 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 246 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 247 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 251 Mental Disorder Drugs Market Recent Developments, 2017-2020
Table 252 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 253 Novatis AG: Product Benchmarking
Table 254 Novatis AG: Recent Developments, 2017-2020
Table 255 GlaxoSmithKline Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 256 GlaxoSmithKline Pharmaceuticals Ltd.: Product Benchmarking
Table 257 GlaxoSmithKline Pharmaceuticals Ltd.: Recent Developments, 2017-2020
Table 258 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 259 Pfizer Inc.: Product Benchmarking
Table 260 Pfizer Inc.: Recent Developments, 2017-2020
Table 261 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 262 AbbVie Inc.: Product Benchmarking
Table 263 AbbVie Inc.: Recent Developments, 2017-2020
Table 264 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 265 Johnson & Johnson: Product Benchmarking
Table 266 Johnson & Johnson: Recent Developments, 2017-2020
Table 267 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 268 AstraZeneca: Product Benchmarking
Table 269 AstraZeneca: Recent Developments, 2017-2020
Table 270 Otsuka Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 271 Otsuka Pharmaceuticals: Product Benchmarking
Table 272 Otsuka Pharmaceuticals: Recent Developments, 2017-2020
Table 273 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 274 Eli Lilly and Company: Product Benchmarking
Table 275 Eli Lilly and Company: Recent Developments, 2017-2020
Table 276 H. Lundbeck A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 277 H. Lundbeck A/S: Product Benchmarking
Table 278 H. Lundbeck A/S: Recent Developments, 2017-2020
Table 279 Takeda Pharmaceutical Company Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 280 Takeda Pharmaceutical Company Ltd.: Product Benchmarking
Table 281 Takeda Pharmaceutical Company Ltd.: Recent Developments, 2017-2020
Table 282 Bausch Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 283 Bausch Health: Product Benchmarking
Table 284 Mallinckrodt Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 285 Mallinckrodt Pharmaceuticals: Product Benchmarking
Table 286 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 287 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 288 Teva Pharmaceutical Industries Ltd.: Recent Developments, 2017-2020
Table 289 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 290 Merck & Co., Inc.: Product Benchmarking
Table 291 Bristol-Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 292 Bristol-Myers Squibb: Product Benchmarking
Table 293 Bristol-Myers Squibb: Recent Developments, 2017-2020
List of Figures
Figure 1 Global Mental Disorder Drugs Market Segmentation
Figure 2 Global Mental Disorder Drugs Market: Market Trends
Figure 3 Global Mental Disorder Drugs Market: SWOT Analysis
Figure 4 Global Mental Disorder Drugs Market: Porter’s Five Forces Analysis
Figure 5 Global Mental Disorder Drugs Market: PEST Analysis
Figure 6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %)
Figure 7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "V" Shaped Recovery
Figure 8 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "U" Shaped Recovery
Figure 9 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "W" Shaped Recovery
Figure 10 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "L" Shaped Recovery
Figure 11 Global Mental Disorder Drugs Market Share Forecast by Drug Class, 2021, 2026, 2031 (%)
Figure 12 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 13 “V” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 14 “U” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 15 “W” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 16 “L” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 17 Global SNRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 18 “V” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 19 “U” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 20 “W” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 21 “L” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 22 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 23 “V” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 24 “U” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 25 “W” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 26 “L” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 27 Global TCAs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 28 “V” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 29 “U” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 30 “W” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 31 “L” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 32 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 33 “V” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 34 “U” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 35 “W” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 36 “L” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 37 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 38 “V” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 39 “U” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 40 “W” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 41 “L” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 42 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 43 “V” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 44 “U” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 45 “W” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 46 “L” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 47 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 48 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 49 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 50 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 51 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 53 “V” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 54 “U” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 55 “W” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 56 “L” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 58 “V” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 59 “U” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 60 “W” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 61 “L” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 63 “V” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 64 “U” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 65 “W” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 66 “L” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 68 “V” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 69 “U” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 70 “W” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 71 “L” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 73 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 74 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 75 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 76 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 77 Global Mental Disorder Drugs Market Share Forecast by Distribution Channel, 2021, 2026, 2031 (%)
Figure 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 88 Global Mental Disorder Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 89 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 90 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 91 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 92 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 93 Global Mental Disorder Drugs Market Share Forecast by Region 2021, 2026, 2031 (%)
Figure 94 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): “V” Shaped Recovery
Figure 95 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): “U” Shaped Recovery
Figure 96 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 97 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 98 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 99 North America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 100 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 101 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 102 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 103 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 104 North America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 105 North America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 117 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 118 Europe Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 119 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 120 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 121 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 122 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 123 Europe Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 124 Europe Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 161 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 163 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 164 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 165 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 166 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 167 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 168 Asia Pacific Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 200 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 201 Latin America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 202 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 203 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 204 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 205 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 206 Latin America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 207 Latin America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 208 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 213 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 218 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 223 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 228 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 229 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 230 MEA Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 231 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 232 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 233 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 234 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 235 MEA Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 236 MEA Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 237 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 241 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 242 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 246 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 247 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 251 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 252 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 253 Global Mental Disorder Drugs Market: Company Share Analysis, 2020
Figure 254 Novatis AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 255 Novatis AG: Product Revenue Shares, 2019
Figure 256 Novartis AG.: Pharmaceuticals Business Unit Revenue Shares, 2019
Figure 257 Novatis AG: Regional Revenue Shares, 2019
Figure 258 GlaxoSmithKline Pharmaceuticals Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 259 GlaxoSmithKline Pharmaceuticals Ltd.: Product Revenue Shares, 2019
Figure 260 GlaxoSmithKline Pharmaceuticals Ltd.: Pharmaceutical Segment Revenue Shares, 2019
Figure 261 GlaxoSmithKline Pharmaceuticals Ltd.: Regional Revenue Shares, 2019
Figure 262 Pfizer Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 263 Pfizer Inc.: Product Revenue Shares, 2019
Figure 264 Pfizer Inc.: Regional Revenue Shares, 2019
Figure 265 AbbVie Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 266 AbbVie Inc.: Product Revenue Shares, 2019
Figure 267 AbbVie Inc.: Regional Revenue Shares, 2019
Figure 268 Johnson & Johnson: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 269 Johnson & Johnson: Pharmaceutical Segment Revenue Shares, 2019
Figure 270 Johnson & Johnson: Business Segment Revenue Shares, 2019
Figure 271 AstraZeneca: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 272 AstraZeneca: Product Revenue Shares, 2019
Figure 273 AstraZeneca: Regional Revenue Shares, 2019
Figure 274 Eli Lilly and Company: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 275 Eli Lilly and Company: Product Revenue Shares, 2019
Figure 276 Eli Lilly and Company: Regional Revenue Shares, 2019
Figure 277 H. Lundbeck A/S: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 278 H. Lundbeck A/S: Regional Revenue Shares, 2019
Figure 279 Takeda Pharmaceutical Company Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 280 Takeda Pharmaceutical Company Ltd.: Regional Revenue Shares, 2019
Figure 281 Bausch Health: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 282 Bausch Health: Product Revenue Shares, 2019
Figure 283 Bausch Health: Regional Revenue Shares, 2019
Figure 284 Mallinckrodt Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 285 Mallinckrodt Pharmaceuticals: Product Revenue Shares, 2019
Figure 286 Mallinckrodt Pharmaceuticals: Regional Revenue Shares, 2019
Figure 287 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 288 Teva Pharmaceutical Industries Ltd.: Product Revenue Shares, 2019
Figure 289 Teva Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2019
Figure 290 Merck & Co., Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 291 Merck & Co., Inc.: Product Revenue Shares, 2019
Figure 292 Merck & Co., Inc.: Regional Revenue Shares, 2019
Figure 293 Bristol-Myers Squibb: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 294 Bristol-Myers Squibb: Regional Revenue Shares, 2019
1.1 Introduction to Mental Disorder Drugs Market
1.1.1 What Is Mental Disorder?
1.1.2 Types of Mental Disorders
1.1.3 Prevalence and Mortality for Mental Disorders
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered By This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecast Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Development of Advanced Mental Disorder Drugs
3.1.2 Increasing Prevalence of Mental Disorders
3.1.3 Escalating of Mental Healthcare Awareness
3.2 Restraints
3.2.1 Increasing Development of Novel Drugs
3.2.2 Social Stigma of Mental Disorders
3.2.3 Stringent Regulatory Guidelines for New Drug Approval
3.3 Opportunities
3.3.1 Growing Demand for Cutting-Edge Therapeutic Treatments for Mental Disorders to Aid Market Growth
3.3.2 Increase in Geriatric Population
3.4 Trends
3.4.1 Mergers, Agreements, and Acquisitions by the Market Players
3.4.2 Expected Launch of New Drugs is Expected to Drive the Market Growth
3.5 SWOT Analysis
3.5.1 Strengths: The Most Dynamic Area of the Mental Disorders Market
3.5.2 Weaknesses
3.5.3 Opportunities
3.5.3.1 Increasing Mergers & Acquisitions and Collaborations
3.5.3.2 Large Amount of R&D Investment
3.5.4 Threats
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Supplier: Moderate
3.6.2 Bargaining Power of Buyer: Moderate
3.6.3 Competitive Rivalry: High
3.6.4 Threat of New Entrants: Moderate
3.6.5 Threat of Substitutes: Moderate
3.7 PEST Analysis
3.7.1 Political Factors Impacting Mental Disorder Drugs Market
3.7.2 Economic Factors Impacting Mental Disorder Drugs Market
3.7.3 Social Factors Impacting Mental Disorder Drugs Market
3.7.4 Technological Factors Impacting Mental Disorder Drugs Market
4 Global Mental Disorder Drugs Market Forecast, 2021-2031
4.1 Global Mental Disorder Drugs Market Forecast 2021-2031
5 COVID-19 Impact: Global Mental Disorder Drugs Market
5.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
5.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
5.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
5.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Drug Class
6.1 Global SSRIs Segment: Revenue Forecast 2021-2031
6.1.1 Largest Revenue Grossing Segment
6.1.2 Recovery Forecasts (V, U, W, L)
6.2 Global SNRIs Segment: Revenue Forecast 2021-2031
6.2.1 Increase in Adoption of These Drugs for the Treatment of Mental Disorders
6.2.2 Recovery Forecasts (V, U, W, L)
6.3 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031
6.3.1 Atypical Antipsychotics Segment is Expected to Grow at a Lucrative Growth Rate
6.3.2 Recovery Forecasts (V, U, W, L)
6.4 Global TCAs Segment: Revenue Forecast 2021-2031
6.4.1 TCAs Play an In the Treatment of Severe Depression
6.4.2 Recovery Forecasts (V, U, W, L)
6.5 Global SARIs Segment: Revenue Forecast 2021-2031
6.5.1 SARIs Are Mainly Used For The Treatment MDD
6.5.2 Recovery Forecasts (V, U, W, L)
6.6 Global Benzodiazepines Segment: Revenue Forecast 2021-2031
6.6.1 Benzodiazepines Segment is Presumed to Witness Moderate Growth over the Forecast Period
6.6.2 Recovery Forecasts (V, U, W, L)
6.7 Global MAOIs Segment: Revenue Forecast 2021-2031
6.7.1 MAOIs Segment Expected To Witness Lucrative CAGR during the Forecast Period
6.7.2 Recovery Forecasts (V, U, W, L)
6.8 Global Others Segment: Revenue Forecast 2021-2031
6.8.1 Growing Demand for Advanced Drugs Is Expected to Propel the Segment Growth
6.8.2 Recovery Forecasts (V, U, W, L)
7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Indication
7.1 Global Depression Segment: Revenue Forecast 2021-2031
7.1.1 Largest Revenue Grossing Segment
7.1.2 Recovery Forecasts (V, U, W, L)
7.2 Global Schizophrenia Segment: Revenue Forecast 2021-2031
7.2.1 Mounting Prevalence of Schizophrenia Worldwide Will Drive the Segment Growth
7.2.2 Recovery Forecasts (V, U, W, L)
7.3 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031
7.3.1 Adoption of Generic Drugs for the Treatment of Bipolar Disorder
7.3.2 Recovery Forecasts (V, U, W, L)
7.4 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031
7.4.1 Growing R&D expenditure in the development of therapeutically advanced mental disorder drugs
7.4.2 Recovery Forecasts (V, U, W, L)
7.5 Global Others Segment: Revenue Forecast 2021-2031
7.5.1 Rising Prevalence of Other Mental Disorders
7.5.2 Recovery Forecasts (V, U, W, L)
8 Mental Disorder Drugs Market by Distribution Channel Forecast, 2021-2031
8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
8.1.1 Largest Revenue Generating Segment
8.1.2 Recovery Scenarios (V, U, W, L)
8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
8.2.1 Fastest Growing Segment in the Market
8.2.2 Recovery Scenarios (V, U, W, L)
8.3 Others Segment Market Forecast, 2021-2031
8.3.1 Developing Healthcare Infrastructure Is Expected To Drive the Market Growth
8.3.2 Recovery Scenarios (V, U, W, L)
9 Global Mental Disorder Drugs Market Forecast, 2021-2031
9.1 Global Mental Disorder Drugs Market by Region Forecast 2021-2031
9.2 Recovery Scenarios (V, U, W, L)
10 North America Mental Disorder Drugs Market, 2021-2031
10.1 North America is The Largest Revenue Grossing Region in the Global Market
10.2 North America Mental Disorder Drugs Market by Country, Forecast 2021-2031
10.3 Recovery Scenarios (V, U, W, L)
10.4 North America Mental Disorder Drugs Market Forecast by Drug Class
10.5 North America Mental Disorder Drugs Market Forecast by Indication
10.6 North America Mental Disorder Drugs Market Forecast by Distribution Channel
10.7 U.S. Mental Disorder Drugs Market Forecast, 2021-2031
10.7.1 Rise in the Number of Drug Approvals
10.7.2 Presence of Highly Developed Healthcare Infrastructure
10.7.3 Recovery Scenarios (V, U, W, L): U.S. Mental Disorder Drugs Market Forecast, 2021-2031
10.8 Canada Mental Disorder Drugs Market Forecast, 2021-2031
10.8.1 Anticipated To Witness the Fastest Growth in the North America Region
10.8.2 Benefits of Manufacturing and R&D Operations in Canada
10.8.3 Recovery Scenarios (V, U, W, L): Canada Mental Disorder Drugs Market Forecast, 2021-2031
11 Europe Mental Disorder Drugs Market, 2021-2031
11.1 Second Largest Market in the Global Market
11.2 Europe Mental Disorder Drugs Market by Country, Forecast 2021-2031
11.3 Recovery Scenarios (V, U, W, L)
11.4 Europe Mental Disorder Drugs Market Forecast by Drug Class
11.5 Europe Mental Disorder Drugs Market Forecast by Indication
11.6 Europe Mental Disorder Drugs Market Forecast by Distribution Channel
11.7 Germany Mental Disorder Drugs Market Forecast, 2021-2031
11.7.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
11.7.2 One of the Oldest Universal Health Systems within Europe
11.7.3 Recovery Scenarios (V, U, W, L): Germany Mental Disorder Drugs Market Forecast, 2021-2031
11.8 UK Mental Disorder Drugs Market Forecast, 2021-2031
11.8.1 Presence of Well-Developed R&D Infrastructure
11.8.2 Increasing Prevalence of Mental Disorders in This Region
11.8.3 Recovery Scenarios (V, U, W, L): UK Mental Disorder Drugs Market Forecast, 2021-2031
11.9 France Mental Disorder Drugs Market Forecast, 2021-2031
11.9.1 Growing Demand For Affordable Healthcare Services
11.9.2 Growing Demand for Innovative Medicine and Pharmaceutical
11.9.3 Recovery Scenarios (V, U, W, L): France Mental Disorder Drugs Market Forecast, 2021-2031
11.10 Italy Mental Disorder Drugs Market Forecast, 2021-2031
11.10.1 Pharmaceutical Manufacturing Hub
11.10.2 Growing Demand for Advanced Therapies for the Treatment of Mental Disorders
11.10.3 Recovery Scenarios (V, U, W, L): Italy Mental Disorder Drugs Market Forecast, 2021-2031
11.11 Spain Mental Disorder Drugs Market Forecast, 2021-2031
11.11.1 Spanish Economy Is Growing Strong
11.11.2 Demand for Drugs Is Influenced By the Growth of the Pharmaceutical Industry
11.11.3 Recovery Scenarios (V, U, W, L): Spain Mental Disorder Drugs Market Forecast, 2021-2031
11.12 Russia Mental Disorder Drugs Market Forecast, 2021-2031
11.12.1 Unmet Pharmaceutical Needs
11.12.2 Government Support For Development of the Healthcare Infrastructure
11.12.3 Recovery Scenarios (V, U, W, L): Russia Mental Disorder Drugs Market Forecast, 2021-2031
11.13 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
11.13.1 Increasing Prevalence of Mental Disorders
11.13.2 Recovery Scenarios (V, U, W, L): Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
12 Asia Pacific Mental Disorder Drugs Market, 2021-2031
12.1 Asia Pacific is the Fastest Growing Market
12.2 Asia Pacific Mental Disorder Drugs Market by Country, Forecast 2021-2031
12.3 Recovery Scenarios (V, U, W, L)
12.4 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class
12.5 Asia Pacific Mental Disorder Drugs Market Forecast by Indication
12.6 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel
12.7 Japan Mental Disorder Drugs Market Forecast, 2021-2031
12.7.1 Japan Accounted For the Largest Market Share in the Asia Pacific Region
12.7.2 Government Initiatives
12.7.3 Recovery Scenarios (V, U, W, L): Japan Mental Disorder Drugs Market Forecast, 2021-2031
12.8 China Mental Disorder Drugs Market Forecast, 2021-2031
12.8.1 Presence of Large Geriatric Population
12.8.2 Increasing Healthcare Spending In China
12.8.3 Recovery Scenarios (V, U, W, L): China Mental Disorder Drugs Market Forecast, 2021-2031
12.9 India Mental Disorder Drugs Market Forecast, 2021-2031
12.9.1 Developing Healthcare Infrastructure
12.9.2 Increasing Prevalence of Mental Disorders
12.9.3 Recovery Scenarios (V, U, W, L): India Mental Disorder Drugs Market Forecast, 2021-2031
12.10 Australia Mental Disorder Drugs Market Forecast, 2021-2031
12.10.1 Government Programs to Expand Access to Quality Eye Care Facilities
12.10.2 Well Established Healthcare Infrastructure
12.10.3 Recovery Scenarios (V, U, W, L): Australia Mental Disorder Drugs Market Forecast, 2021-2031
12.11 South Korea Mental Disorder Drugs Market Forecast, 2021-2031
12.11.1 Growing Healthcare Awareness among People
12.11.2 Increasing Prevalence of Depression
12.11.3 Recovery Scenarios (V, U, W, L): South Korea Mental Disorder Drugs Market Forecast, 2021-2031
12.12 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
12.12.1 Rising Disposable Income
12.12.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
13 Latin America Mental Disorder Drugs Market, 2021-2031
13.1 Latin America Mental Disorder Drugs Market
13.2 Latin America Mental Disorder Drugs Market by Country, Forecast 2021-2031
13.3 Recovery Scenarios (V, U, W, L)
13.4 Latin America Mental Disorder Drugs Market Forecast by Drug Class
13.5 Latin America Mental Disorder Drugs Market Forecast by Indication
13.6 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel
13.7 Brazil Mental Disorder Drugs Market Forecast, 2021-2031
13.7.1 Fastest Growing Economies in Latin America
13.7.2 Government Incentives to Keep Manufacturing Local
13.7.3 Recovery Scenarios (V, U, W, L): Brazil Mental Disorder Drugs Market Forecast, 2021-2031
13.8 Mexico Mental Disorder Drugs Market Forecast, 2021-2031
13.8.1 Lower Manufacturing Costs than In the US
13.8.2 Favourable Initiatives Undertaken By Private and Public Sectors
13.8.3 Recovery Scenarios (V, U, W, L): Mexico Mental Disorder Drugs Market Forecast, 2021-2031
13.9 Argentina Mental Disorder Drugs Market Forecast, 2021-2031
13.9.1 Boom in Pharmaceutical Industry
13.9.2 Adoption of Depression and Other Mental Disorders Drugs
13.9.3 Recovery Scenarios (V, U, W, L): Argentina Mental Disorder Drugs Market Forecast, 2021-2031
13.10 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
13.10.1 Developing Healthcare Infrastructure
13.10.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
14 MEA Mental Disorder Drugs Market, 2021-2031
14.1 Rising Prevalence of Mental Disorders
14.2 MEA Mental Disorder Drugs Market by Country, Forecast 2021-2031
14.3 Recovery Scenarios (V, U, W, L)
14.4 MEA Mental Disorder Drugs Market Forecast by Drug Class
14.5 MEA Mental Disorder Drugs Market Forecast by Indication
14.6 MEA Mental Disorder Drugs Market Forecast by Distribution Channel
14.7 South Africa Mental Disorder Drugs Market Forecast, 2021-2031
14.7.1 Increasing Focus of Pharmaceutical & Pharmaceutical Companies in This Region
14.7.2 Supportive Government Initiatives
14.7.3 Recovery Scenarios (V, U, W, L): South Africa Mental Disorder Drugs Market Forecast, 2021-2031
14.8 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
14.8.1 Presence of Huge Growth Opportunities
14.8.2 Presence of Huge Growth Opportunities
14.8.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
14.9 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
14.9.1 Strong Presence Of Leading Companies
14.9.2 Growing Prevalence of Mental Disorders
14.9.3 Recovery Scenarios (V, U, W, L): Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
15 Company Profiles
15.1 Company Share Analysis
15.2 Mental Disorder Drugs Market Recent Developments, 2017-2020
15.3 Novartis AG
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2015-2019
15.3.3.2 Product Revenue Shares, 2019
15.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
15.3.3.4 Regional Revenue Shares, 2019
15.3.4 Product Benchmarking
15.3.5 Recent Developments, 2017-2020
15.4 GlaxoSmithKline Pharmaceuticals Ltd.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2015-2019
15.4.3.2 Product Revenue Shares, 2019
15.4.3.3 Pharmaceuticals Segment Revenue Shares, 2019
15.4.3.4 Regional Revenue Shares, 2019
15.4.4 Product Benchmarking
15.4.5 Recent Developments, 2017-2020
15.5 Pfizer Inc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2015-2019
15.5.3.2 Product Revenue Shares, 2019
15.5.3.3 Regional Revenue Shares, 2019
15.5.4 Product Benchmarking
15.5.5 Recent Developments, 2017-2020
15.6 AbbVie Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2015-2019
15.6.3.2 Product Revenue Shares, 2019
15.6.3.3 Regional Revenue Shares, 2019
15.6.4 Product Benchmarking
15.6.5 Recent Developments, 2017-2020
15.7 Johnson & Johnson
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2015-2019
15.7.3.2 Product Revenue Shares, 2019
15.7.3.3 Regional Revenue Shares, 2019
15.7.4 Product Benchmarking
15.7.5 Recent Developments, 2017-2020
15.8 AstraZeneca
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2015-2019
15.8.3.2 Product Revenue Shares, 2019
15.8.3.3 Regional Revenue Shares, 2019
15.8.4 Product Benchmarking
15.8.5 Recent Developments, 2017-2020
15.9 Otsuka Pharmaceuticals
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Recent Developments, 2017-2020
15.10 Eli Lilly and Company
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2015-2019
15.10.3.2 Product Revenue Shares, 2019
15.10.3.3 Regional Revenue Shares, 2019
15.10.4 Product Benchmarking
15.10.5 Recent Developments, 2017-2020
15.11 H. Lundbeck A/S
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2015-2019
15.11.3.2 Regional Revenue Shares, 2019
15.11.4 Product Benchmarking
15.11.5 Recent Developments, 2017-2020
15.12 Takeda Pharmaceutical Company Ltd.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2015-2019
15.12.3.2 Regional Revenue Shares, 2019
15.12.4 Product Benchmarking
15.12.5 Recent Developments, 2017-2020
15.13 Bausch Health
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2015-2019
15.13.3.2 Product Revenue Shares, 2019
15.13.3.3 Regional Revenue Shares, 2019
15.13.4 Product Benchmarking
15.14 Mallinckrodt Pharmaceuticals
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2015-2019
15.14.3.2 Product Revenue Shares, 2019
15.14.3.3 Regional Revenue Shares, 2019
15.14.4 Product Benchmarking
15.15 Teva Pharmaceutical Industries Ltd.
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2015-2019
15.15.3.2 Product Revenue Shares, 2019
15.15.3.3 Regional Revenue Shares, 2019
15.15.4 Product Benchmarking
15.15.5 Recent Developments, 2017-2020
15.16 Merck & Co., Inc.
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Financial Analysis
15.16.3.1 Net Revenue, 2015-2019
15.16.3.2 Product Revenue Shares, 2019
15.16.3.3 Regional Revenue Shares, 2019
15.16.4 Product Benchmarking
15.17 Bristol-Myers Squibb
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Financial Analysis
15.17.3.1 Net Revenue, 2015-2019
15.17.3.2 Regional Revenue Shares, 2019
15.17.4 Product Benchmarking
15.17.5 Recent Developments, 2017-2020
16 Conclusion and Recommendations
16.1 Conclusion
16.2 Recommendations
List of Tables
Table 1 Mental Disorder Types
Table 2 Global Mental Disorder Drugs Market, 2021 & 2031 (US$ bn, CAGR %)
Table 3 Worldwide Mental Disorders Prevalence, 2017
Table 4 Major M&A and Collaborations: Mental Disorder Drugs Market
Table 5 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
Table 6 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
Table 7 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
Table 8 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
Table 9 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
Table 10 Global Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 11 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 12 “V” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 13 “U” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 14 “W” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 15 “L” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 16 Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 17 “V” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 18 “U” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 19 “W” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 20 “L” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 21 Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
Table 22 “V” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 23 “U” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 24 “W” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 25 “L” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 26 Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 27 “V” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 28 “U” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 29 “W” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 30 “L” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 31 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 32 “V” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 33 “U” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 34 “W” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 35 “L” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 36 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 37 “V” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 38 “U” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 39 “W” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 40 “L” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 41 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 42 “V” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 43 “U” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 44 “W” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 45 “L” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 46 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 47 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 48 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 49 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 50 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 51 Global Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 53 “V” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 54 “U” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 55 “W” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 56 “L” Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 58 “V” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 59 “U” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 60 “W” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 61 “L” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 63 “V” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 64 “U” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 65 “W” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 66 “L” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 68 “V” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 69 “U” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 70 “W” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 71 “L” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 73 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 74 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 75 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 76 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
Table 77 Global Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 88 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 89 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 90 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 91 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 92 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 93 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 94 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 95 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 96 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 97 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 98 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 99 North America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 100 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 101 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 102 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 103 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 104 North America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 105 North America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 117 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 118 Europe Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 119 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 120 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 121 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 122 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 123 Europe Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 124 Europe Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR %)
Table 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 161 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 163 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 164 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 165 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 166 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 167 Asia Pacific Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 168 Asia Pacific Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 200 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 201 Latin America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 202 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 203 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 1 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 204 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 205 Latin America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 206 Latin America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 207 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 208 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 213 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 218 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 223 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 2 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 228 MEA Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 229 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 230 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 231 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 232 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 233 MEA Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 234 MEA Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
Table 235 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 236 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 237 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 241 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 242 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 246 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 247 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 251 Mental Disorder Drugs Market Recent Developments, 2017-2020
Table 252 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 253 Novatis AG: Product Benchmarking
Table 254 Novatis AG: Recent Developments, 2017-2020
Table 255 GlaxoSmithKline Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 256 GlaxoSmithKline Pharmaceuticals Ltd.: Product Benchmarking
Table 257 GlaxoSmithKline Pharmaceuticals Ltd.: Recent Developments, 2017-2020
Table 258 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 259 Pfizer Inc.: Product Benchmarking
Table 260 Pfizer Inc.: Recent Developments, 2017-2020
Table 261 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 262 AbbVie Inc.: Product Benchmarking
Table 263 AbbVie Inc.: Recent Developments, 2017-2020
Table 264 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 265 Johnson & Johnson: Product Benchmarking
Table 266 Johnson & Johnson: Recent Developments, 2017-2020
Table 267 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 268 AstraZeneca: Product Benchmarking
Table 269 AstraZeneca: Recent Developments, 2017-2020
Table 270 Otsuka Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 271 Otsuka Pharmaceuticals: Product Benchmarking
Table 272 Otsuka Pharmaceuticals: Recent Developments, 2017-2020
Table 273 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 274 Eli Lilly and Company: Product Benchmarking
Table 275 Eli Lilly and Company: Recent Developments, 2017-2020
Table 276 H. Lundbeck A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 277 H. Lundbeck A/S: Product Benchmarking
Table 278 H. Lundbeck A/S: Recent Developments, 2017-2020
Table 279 Takeda Pharmaceutical Company Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 280 Takeda Pharmaceutical Company Ltd.: Product Benchmarking
Table 281 Takeda Pharmaceutical Company Ltd.: Recent Developments, 2017-2020
Table 282 Bausch Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 283 Bausch Health: Product Benchmarking
Table 284 Mallinckrodt Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 285 Mallinckrodt Pharmaceuticals: Product Benchmarking
Table 286 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 287 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 288 Teva Pharmaceutical Industries Ltd.: Recent Developments, 2017-2020
Table 289 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 290 Merck & Co., Inc.: Product Benchmarking
Table 291 Bristol-Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 292 Bristol-Myers Squibb: Product Benchmarking
Table 293 Bristol-Myers Squibb: Recent Developments, 2017-2020
List of Figures
Figure 1 Global Mental Disorder Drugs Market Segmentation
Figure 2 Global Mental Disorder Drugs Market: Market Trends
Figure 3 Global Mental Disorder Drugs Market: SWOT Analysis
Figure 4 Global Mental Disorder Drugs Market: Porter’s Five Forces Analysis
Figure 5 Global Mental Disorder Drugs Market: PEST Analysis
Figure 6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %)
Figure 7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "V" Shaped Recovery
Figure 8 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "U" Shaped Recovery
Figure 9 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "W" Shaped Recovery
Figure 10 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "L" Shaped Recovery
Figure 11 Global Mental Disorder Drugs Market Share Forecast by Drug Class, 2021, 2026, 2031 (%)
Figure 12 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 13 “V” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 14 “U” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 15 “W” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 16 “L” Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 17 Global SNRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 18 “V” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 19 “U” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 20 “W” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 21 “L” Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 22 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 23 “V” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 24 “U” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 25 “W” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 26 “L” Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 27 Global TCAs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 28 “V” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 29 “U” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 30 “W” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 31 “L” Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 32 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 33 “V” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 34 “U” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 35 “W” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 36 “L” Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 37 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 38 “V” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 39 “U” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 40 “W” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 41 “L” Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 42 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 43 “V” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 44 “U” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 45 “W” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 46 “L” Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 47 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 48 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 49 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 50 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 51 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 53 “V” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 54 “U” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 55 “W” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 56 “L” Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 58 “V” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 59 “U” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 60 “W” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 61 “L” Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 63 “V” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 64 “U” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 65 “W” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 66 “L” Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 68 “V” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 69 “U” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 70 “W” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 71 “L” Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 73 “V” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 74 “U” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 75 “W” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 76 “L” Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 77 Global Mental Disorder Drugs Market Share Forecast by Distribution Channel, 2021, 2026, 2031 (%)
Figure 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 88 Global Mental Disorder Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 89 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 90 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 91 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 92 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 93 Global Mental Disorder Drugs Market Share Forecast by Region 2021, 2026, 2031 (%)
Figure 94 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): “V” Shaped Recovery
Figure 95 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): “U” Shaped Recovery
Figure 96 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 97 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 98 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 99 North America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 100 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 101 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 102 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 103 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 104 North America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 105 North America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 117 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 118 Europe Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 119 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 120 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 121 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 122 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 123 Europe Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 124 Europe Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 161 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 163 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 164 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 165 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 166 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 167 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 168 Asia Pacific Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 200 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 201 Latin America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 202 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 203 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 204 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 205 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 206 Latin America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 207 Latin America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 208 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 213 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 218 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 223 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 228 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 229 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
Figure 230 MEA Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 231 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 232 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 233 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 234 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 235 MEA Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
Figure 236 MEA Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
Figure 237 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
Figure 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 241 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 242 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 246 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 247 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 251 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 252 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 253 Global Mental Disorder Drugs Market: Company Share Analysis, 2020
Figure 254 Novatis AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 255 Novatis AG: Product Revenue Shares, 2019
Figure 256 Novartis AG.: Pharmaceuticals Business Unit Revenue Shares, 2019
Figure 257 Novatis AG: Regional Revenue Shares, 2019
Figure 258 GlaxoSmithKline Pharmaceuticals Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 259 GlaxoSmithKline Pharmaceuticals Ltd.: Product Revenue Shares, 2019
Figure 260 GlaxoSmithKline Pharmaceuticals Ltd.: Pharmaceutical Segment Revenue Shares, 2019
Figure 261 GlaxoSmithKline Pharmaceuticals Ltd.: Regional Revenue Shares, 2019
Figure 262 Pfizer Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 263 Pfizer Inc.: Product Revenue Shares, 2019
Figure 264 Pfizer Inc.: Regional Revenue Shares, 2019
Figure 265 AbbVie Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 266 AbbVie Inc.: Product Revenue Shares, 2019
Figure 267 AbbVie Inc.: Regional Revenue Shares, 2019
Figure 268 Johnson & Johnson: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 269 Johnson & Johnson: Pharmaceutical Segment Revenue Shares, 2019
Figure 270 Johnson & Johnson: Business Segment Revenue Shares, 2019
Figure 271 AstraZeneca: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 272 AstraZeneca: Product Revenue Shares, 2019
Figure 273 AstraZeneca: Regional Revenue Shares, 2019
Figure 274 Eli Lilly and Company: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 275 Eli Lilly and Company: Product Revenue Shares, 2019
Figure 276 Eli Lilly and Company: Regional Revenue Shares, 2019
Figure 277 H. Lundbeck A/S: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 278 H. Lundbeck A/S: Regional Revenue Shares, 2019
Figure 279 Takeda Pharmaceutical Company Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 280 Takeda Pharmaceutical Company Ltd.: Regional Revenue Shares, 2019
Figure 281 Bausch Health: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 282 Bausch Health: Product Revenue Shares, 2019
Figure 283 Bausch Health: Regional Revenue Shares, 2019
Figure 284 Mallinckrodt Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 285 Mallinckrodt Pharmaceuticals: Product Revenue Shares, 2019
Figure 286 Mallinckrodt Pharmaceuticals: Regional Revenue Shares, 2019
Figure 287 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 288 Teva Pharmaceutical Industries Ltd.: Product Revenue Shares, 2019
Figure 289 Teva Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2019
Figure 290 Merck & Co., Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 291 Merck & Co., Inc.: Product Revenue Shares, 2019
Figure 292 Merck & Co., Inc.: Regional Revenue Shares, 2019
Figure 293 Bristol-Myers Squibb: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 294 Bristol-Myers Squibb: Regional Revenue Shares, 2019
Companies Profiled in the Report
AbbVie Inc.
AstraZeneca
Bausch Health
Bristol Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline Pharmaceuticals Ltd.
H. Lundbeck A/S
Johnson and Johnson
Mallinckrodt Pharmaceuticals
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
List of Companies Mentioned in the Report
AbbVie Inc.
Actelion Ltd
Allergan plc
AstraZeneca
Aurobindo Pharma
Bausch Health
Bristol Myers Squibb Company
Cadent Therapeutics
Celgene Corporation
Concordia Pharms Inc
Dr. Reddy’s Labs
Eli Lilly and Company
Gedeon Richter Plc.
GlaxoSmithKline Pharmaceuticals Ltd.
H. Lundbeck A/S
Hoffmann-La Roche
Janssen Holding GmbH
Janssen Pharmaceutical
Janssen Research & Development, LLC
Jazz Pharmaceuticals, Inc.
Johnson and Johnson
Lupin Ltd.
Mallinckrodt Pharmaceuticals
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Orchard Therapeutics
Osmotica Pharmaceutical Corp.
Otsuka Pharmaceutical Co., Ltd.
Par Pharmaceutical
Pear Therapeutics, Inc.,
Pfizer Inc.
Proteus Digital Health (Proteus)
Sandoz
Sanofi SA (France)
Sebela International Ltd.
Somerset Pharmaceuticals, Inc.
Strateos, Inc.
Sun Pharmaceuticals
Takeda Pharmaceutical Company Ltd
Teva Canada Limited
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals
List of Organizations Mentioned in the Report
Australian Government
Australian Institute of Health and Welfare
CAMH (Centre for Addiction and Mental Health)
Centers for Disease Control and Prevention (CDC)
Child Mind Institute
China’s Ministry of Finance
Chinese government
European Union
EXIM bank
FDA Centre’s for Drug Evaluation and Research
French Government
Government of Japan
Health Ministry (Italy)
Institute for Healthcare Improvement (IHI)
Italian Industry Group Farmindustria
Japanese Ministry of Health, Labour and Welfare
King Salman Humanitarian Aids & Relief Center
MHFA England
National Development and Reform Commission (NDRC)
National Institute of Health (NIH)
National Mental Health Institute
NCBI
NHS England
NHS England 's House of Care
Organisation for Economic Co-operation and Development (OECD)
Saudi Export Development Authority
US government
WHO
World Bank
World Economic Forum (WEF)
AbbVie Inc.
AstraZeneca
Bausch Health
Bristol Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline Pharmaceuticals Ltd.
H. Lundbeck A/S
Johnson and Johnson
Mallinckrodt Pharmaceuticals
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
List of Companies Mentioned in the Report
AbbVie Inc.
Actelion Ltd
Allergan plc
AstraZeneca
Aurobindo Pharma
Bausch Health
Bristol Myers Squibb Company
Cadent Therapeutics
Celgene Corporation
Concordia Pharms Inc
Dr. Reddy’s Labs
Eli Lilly and Company
Gedeon Richter Plc.
GlaxoSmithKline Pharmaceuticals Ltd.
H. Lundbeck A/S
Hoffmann-La Roche
Janssen Holding GmbH
Janssen Pharmaceutical
Janssen Research & Development, LLC
Jazz Pharmaceuticals, Inc.
Johnson and Johnson
Lupin Ltd.
Mallinckrodt Pharmaceuticals
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Orchard Therapeutics
Osmotica Pharmaceutical Corp.
Otsuka Pharmaceutical Co., Ltd.
Par Pharmaceutical
Pear Therapeutics, Inc.,
Pfizer Inc.
Proteus Digital Health (Proteus)
Sandoz
Sanofi SA (France)
Sebela International Ltd.
Somerset Pharmaceuticals, Inc.
Strateos, Inc.
Sun Pharmaceuticals
Takeda Pharmaceutical Company Ltd
Teva Canada Limited
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals
List of Organizations Mentioned in the Report
Australian Government
Australian Institute of Health and Welfare
CAMH (Centre for Addiction and Mental Health)
Centers for Disease Control and Prevention (CDC)
Child Mind Institute
China’s Ministry of Finance
Chinese government
European Union
EXIM bank
FDA Centre’s for Drug Evaluation and Research
French Government
Government of Japan
Health Ministry (Italy)
Institute for Healthcare Improvement (IHI)
Italian Industry Group Farmindustria
Japanese Ministry of Health, Labour and Welfare
King Salman Humanitarian Aids & Relief Center
MHFA England
National Development and Reform Commission (NDRC)
National Institute of Health (NIH)
National Mental Health Institute
NCBI
NHS England
NHS England 's House of Care
Organisation for Economic Co-operation and Development (OECD)
Saudi Export Development Authority
US government
WHO
World Bank
World Economic Forum (WEF)
Download sample pages
Complete the form below to download your free sample pages for Mental Disorder Drugs Market Report 2021-2031Related reports
-
Behavioral/Mental Health Care Software & Services Market Report 2019-2029
Behavioral/Mental Health Care Software & Services Report is a specialized and in-depth study of the medical devices industry with a...
Full DetailsPublished: 01 January 1970 -
Behavioural Health Market Report to 2031
Where is the Global Behavioral Health market heading? If you are involved in this sector you must read this newly...Full DetailsPublished: 01 January 1970 -
CNS Therapeutics Market Report 2021-2031
Due to the rapid transmittal of the disease, there has been a sharp increase in number of cases worldwide. While...Full DetailsPublished: 25 January 2021 -
Cannabidiol Market Report 2020-2030
Where is the Cannabidiol Market heading? If you are involved in this sector you must read this newly updated report....
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Mental Disorder Drugs Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
